Compare Sanofi SA (SNY) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wendys Co — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Wendys Co trades at $6.23 (market cap $1.19B). The key difference: Sanofi SA is far larger — about 80× Wendys Co's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Wendys Co for 77 Days on average.
| SNY | WEN | |
|---|---|---|
Market Cap | $95.18B | $1.19B |
Volume | 2,995,646 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $9.33 |
52-Week Low | $39.51 | $6.10 |
Typical Hold Time | 94 Days | 77 Days |
Enterprise Value | $114.48B | $4.92B |
Dividend Yield | 6.01% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Wendy's (WEN) trades at $6.22, up 1.8% today but remains in a bearish technical trend with declining fundamentals. Revenue has stagnated around $2.2B, while net income fell to $165M in 2025, with a projected drop to $126M in 2026. The stock appears undervalued with a P/E of 9.45 and P/S of 0.54, but faces headwinds from a major franchisee bankruptcy and six consecutive quarters of same-store sales declines.
The outlook is cautious due to operational challenges and high debt, though the low valuation and consistent dividend offer some support. Analyst consensus is a 'Hold' with a $7.58 price target, reflecting skepticism about near-term recovery. Key risks include competitive pressure, execution missteps, and macroeconomic strain on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
